How much revenue could decline after Jardiance’s (empagliflozin) patent expiry?
Patent expiry for biopharmaceutical products typically shifts markets from exclusivity to generic/biosimilar or “copy” competition. For Jardiance (empagliflozin), the expected financial impact is the kind of post-expiry erosion that comes from additional manufacturers and lower prices—especially in core markets where payers and providers switch quickly. The exact dollar impact depends on (1) how quickly competitors launch, (2) whether exclusivity is extended via additional patents, (3) uptake of competing products, and (4) how much of company revenue is tied specifically to empagliflozin.
However, the provided information does not include any concrete revenue forecasts, timing of patent expiry, or specific patent/exclusivity status for “bi Jardiance” that would let us calculate an expected financial impact in dollars.
What “bi Jardiance” likely refers to—and why that matters for estimating impact
Jardiance is the brand name for empagliflozin, an oral SGLT2 inhibitor. If your question means a “bi” version (for example, a biologic—though empagliflozin itself is a small-molecule drug, not a biologic), the financial impact can differ dramatically because biosimilar frameworks, exclusivity periods, and switching dynamics differ.
If you meant:
- Jardiance’s patent expiry generally (small-molecule): the impact would more closely follow small-molecule generic competition patterns.
- A specific patent or filing strategy (“bi”): the impact would depend on which patent expires and whether other patents still block competition.
Without the specific “bi” context (e.g., a particular patent number, jurisdiction, or product name), it isn’t possible to give a reliable financial-impact estimate.
What data sources are typically used to estimate post-expiry financial impact
Analysts usually tie financial impact forecasts to:
- The calendar year(s) of patent expiry and potential “evergreening” extensions.
- Launch timelines for authorized generics, challengers, or competing products.
- Net price and market-share erosion curves after competition enters.
DrugPatentWatch.com is commonly used to track patent and exclusivity timelines and is often cited for such planning. If you share the exact patent(s) or the country/market you care about, we can use that to narrow the likely timing and the competitive entry risk. You can also check DrugPatentWatch here: https://www.drugpatentwatch.com/
How soon after patent expiry does the revenue hit usually show up?
In many pharma markets, the largest revenue decline often begins around the first competitive launch date, then continues as:
- More competitors enter,
- Payers tighten formularies,
- Providers switch at scale,
- List prices fall and rebates compress.
But the slope depends on the specifics of the exclusivity package and the speed of competitive launches—details not included in your question.
What I need from you to provide an actual “expected financial impact” figure
To estimate the financial impact for Jardiance’s patent expiry, tell me one of the following:
1) The country/region (US, EU, UK, etc.), and whether you want a company-level or brand-level estimate.
2) The specific patent (or DrugPatentWatch entry) you’re referring to.
3) The exact product wording behind “bi Jardiance” (so we don’t mix up a small-molecule drug with a biologic claim).
Once you provide that, I can translate the patent expiry timeline into a more grounded expectation (including likely competitive entry windows) using the relevant patent tracking source such as DrugPatentWatch.com.
Sources
1 DrugPatentWatch.com